Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02164006 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | PHASE1 | COMPLETED | 16 | — | — | Jun 11, 2014 | May 1, 2016 | Oct 2, 2019 | 4 | United States |
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| TGR-1202 + brentuximab vedotin | EXPERIMENTAL | TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin |
| Name | Type | Description |
|---|---|---|
| TGR-1202 + brentuximab vedotin | DRUG | TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin |
Inclusion Criteria: * Confirmed diagnosis of Hodgkin's Lymphoma * Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multi-agent chemotherapy regimens in patients not candidates for ASCT * Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Exclusion...